CFAR offered a general Pilot Award program from 1994 to 2017 and funded 82 early stage investigators.
In 2022, CFAR initiated a new program: Pilot Award for Investigators New to HIV.
82 Awards
-
Immunologic Biomarkers for Ruling-out Active Tuberculosis in HIV/AIDS
Immunologic Biomarkers for Ruling-out Active Tuberculosis in HIV/AIDS
Abstract
A point-of-care (POC) test that could be implemented at peripheral levels of the health system in low-income countries has been predicted to reduce tuberculosis (TB)-related mortality by one-third. However, no truly POC test is in the diagnostic pipeline. For maximum impact, a POC test should have high specificity such that a positive test result can be followed by the immediate initiation of treatment. However, a highly sensitive but less specific POC test is a more realistic short-term goal and could be used as an important screening tool in peripheral health care settings ?
-
Solving the Puzzle: HIV-1 Restriction by Innate-associated HLA-Mediated Mechanisms
Solving the Puzzle: HIV-1 Restriction by Innate-associated HLA-Mediated Mechanisms
Abstract
Remarkable advances have helped to determine how immune responses act to contain HIV-1 infection, but precise immune correlates of protection still remain largely uncharacterized. The HLA region is a major determinant of genetics linked to viral control. HLA-B*57+ individuals are known to progress slowly to disease, and this allele is overrepresented in elite controllers. My preliminary results show a reduced replicative capacity of HIV-1 in PBMC from seronegative HLA-B*57+ subjects, in comparison to PBMC from subjects carrying HLA-B*35, an allele associated with rapid disease progression.
-
Solving the Puzzle: HIV-1 Restriction by Innate-associated HLA-Mediated Mechanisms
Solving the Puzzle: HIV-1 Restriction by Innate-associated HLA-Mediated Mechanisms
Abstract
Remarkable advances have helped to determine how immune responses act to contain HIV-1 infection, but precise immune correlates of protection still remain largely uncharacterized. The HLA region is a major determinant of genetics linked to viral control. HLA-B*57+ individuals are known to progress slowly to disease, and this allele is overrepresented in elite controllers. My preliminary results show a reduced replicative capacity of HIV-1 in PBMC from seronegative HLA-B*57+ subjects, in comparison to PBMC from subjects carrying HLA-B*35, an allele associated with rapid disease progression.
-
Qualitative evaluation of a large "test and treat" trial: Characterizing baseline community contexts and implementation processes in SEARCH
Qualitative evaluation of a large "test and treat" trial: Characterizing baseline community contexts and implementation processes in SEARCH
Abstract
A key challenge of large-scale intervention trials is to adequately describe the social, cultural and operational factors that influence study findings. Qualitative research methods are particularly useful for elucidating the processes through which such trials may affect primary clinical outcomes through social and behavioral change at the community level. This pilot award would launch the qualitative evaluation of a large "test and treat" intervention, the Sustainable East Africa Research in Community Health (SEARCH) trial.
-
Qualitative evaluation of a large "test and treat" trial: Characterizing baseline community contexts and implementation processes in SEARCH
Qualitative evaluation of a large "test and treat" trial: Characterizing baseline community contexts and implementation processes in SEARCH
Abstract
A key challenge of large-scale intervention trials is to adequately describe the social, cultural and operational factors that influence study findings. Qualitative research methods are particularly useful for elucidating the processes through which such trials may affect primary clinical outcomes through social and behavioral change at the community level. This pilot award would launch the qualitative evaluation of a large "test and treat" intervention, the Sustainable East Africa Research in Community Health (SEARCH) trial.
-
HIV, HCV, and Fatty liver Disease: Host, Virus or Genes
HIV, HCV, and Fatty liver Disease: Host, Virus or Genes
Abstract
As the prevalence of metabolic syndrome and obesity rises, and as more effective HCV treatments become available, fatty liver disease will likely become a leading cause of liver disease in persons living with HIV. The purpose of this study is to determine the association of metabolic, host genetic, and viral factors with hepatic steatosis (Aim 1) and hepatic fibrosis (Aim 2) in HIV-infected adults with and without HCV coinfection.
-
HIV, HCV, and Fatty liver Disease: Host, Virus or Genes
HIV, HCV, and Fatty liver Disease: Host, Virus or Genes
Abstract
As the prevalence of metabolic syndrome and obesity rises, and as more effective HCV treatments become available, fatty liver disease will likely become a leading cause of liver disease in persons living with HIV. The purpose of this study is to determine the association of metabolic, host genetic, and viral factors with hepatic steatosis (Aim 1) and hepatic fibrosis (Aim 2) in HIV-infected adults with and without HCV coinfection.
-
Strategies to Obtain Systematic Samples and Measure HIV Prevalence in Migrant Women in Western Kenya
Strategies to Obtain Systematic Samples and Measure HIV Prevalence in Migrant Women in Western Kenya
Abstract
This one-year study addresses a neglected topic in HIV research in Africa: the HIV prevention needs of female migrants. The study will address critical gaps in research on methods to obtain valid probability based samples of migrant women and to estimate HIV prevalence in this population at high HIV acquisition and transmission risks. It provides data needed to enhance the study "Identifying Opportunities for HIV Prevention Among Female Migrants in Western Kenya" (K01MH093205-02, Camlin), a qualitative study of factors that facilitate HIV risks among female migrants.
-
Strategies to Obtain Systematic Samples and Measure HIV Prevalence in Migrant Women in Western Kenya
Strategies to Obtain Systematic Samples and Measure HIV Prevalence in Migrant Women in Western Kenya
Abstract
This one-year study addresses a neglected topic in HIV research in Africa: the HIV prevention needs of female migrants. The study will address critical gaps in research on methods to obtain valid probability based samples of migrant women and to estimate HIV prevalence in this population at high HIV acquisition and transmission risks. It provides data needed to enhance the study "Identifying Opportunities for HIV Prevention Among Female Migrants in Western Kenya" (K01MH093205-02, Camlin), a qualitative study of factors that facilitate HIV risks among female migrants.
-
Aging, Cognitive Impairment and Ability to Engage in Healthcare Following Incarceration
Aging, Cognitive Impairment and Ability to Engage in Healthcare Following Incarceration
Abstract
HIV treatment can improve health and longevity and prevent transmission to sexual and injection drug contacts of persons with HIV. However, realizing the benefits of treatment requires consistent engagement in clinical care and adherence to anti-retroviral medication. Both HIV infection and aging are associated with neurocognitive decline. There may also be synergistic effects between HIV infection and aging that accelerate declines in cognitive function. Cognitive impairment may limit individuals? ability to engage in care, particularly in populations where co-morbidities are common.